Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | 17-AAG | 0.031623 | uM | 9 | 156.25 | 92.36 | 61.00 | 112.50 | 0.5422 | -0.7673 |
| SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 81.00 | 112.50 | 0.7200 | -0.3696 | |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 296.00 | 336.50 | 0.8796 | 0.6845 | |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 352.00 | 336.50 | 1.0461 | 1.1243 | |
| SK-BR-3 | Erlotinib | 0.0033113 | uM | 9 | 312.50 | 200.50 | 385.00 | 336.50 | 1.1441 | 1.3950 |
| SK-BR-3 | 17-AAG | 0.001 | uM | 9 | 312.50 | 200.50 | 300.00 | 336.50 | 0.8915 | 0.7151 |
| SK-BR-3 | 17-AAG | 0.000066069 | uM | 9 | 312.50 | 200.50 | 446.00 | 336.50 | 1.3254 | 1.9162 |
| SK-BR-3 | Linsitinib | 3.1623 | uM | 9 | 312.50 | 200.50 | 335.00 | 336.50 | 0.9955 | 0.9881 |
| SK-BR-3 | Erlotinib | 19.9526 | uM | 9 | 312.50 | 200.50 | 396.00 | 336.50 | 1.1768 | 1.4871 |
| SK-BR-3 | Lapatinib | 0.1 | uM | 9 | 312.50 | 200.50 | 305.00 | 336.50 | 0.9064 | 0.7534 |
| SK-BR-3 | Lapatinib | 0.0016596 | uM | 9 | 312.50 | 200.50 | 380.00 | 336.50 | 1.1293 | 1.3535 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 622.00 | 336.50 | 1.8484 | 3.5519 | |
| SK-BR-3 | 17-AAG | 0.1 | uM | 9 | 312.50 | 200.50 | 169.00 | 336.50 | 0.5022 | -0.2045 |
| SK-BR-3 | Erlotinib | 0.1 | uM | 9 | 312.50 | 200.50 | 440.00 | 336.50 | 1.3076 | 1.8638 |
| SK-BR-3 | Lapatinib | 0.31623 | uM | 9 | 312.50 | 200.50 | 218.00 | 336.50 | 0.6479 | 0.1185 |
| SK-BR-3 | Linsitinib | 0.31623 | uM | 9 | 312.50 | 200.50 | 356.00 | 336.50 | 1.0579 | 1.1567 |
| SK-BR-3 | Lapatinib | 0.01 | uM | 9 | 312.50 | 200.50 | 307.00 | 336.50 | 0.9123 | 0.7688 |
| SK-BR-3 | Linsitinib | 0.031623 | uM | 9 | 312.50 | 200.50 | 368.00 | 336.50 | 1.0936 | 1.2545 |
| SK-BR-3 | Erlotinib | 0.031623 | uM | 9 | 312.50 | 200.50 | 386.00 | 336.50 | 1.1471 | 1.4034 |
| SK-BR-3 | Erlotinib | 1 | uM | 9 | 312.50 | 200.50 | 355.00 | 336.50 | 1.0550 | 1.1485 |
| SK-BR-3 | 17-AAG | 0.000302 | uM | 9 | 312.50 | 200.50 | 320.00 | 336.50 | 0.9510 | 0.8698 |
| SK-BR-3 | Lapatinib | 3.1623 | uM | 9 | 312.50 | 200.50 | 140.00 | 336.50 | 0.4161 | -0.3817 |
| SK-BR-3 | 17-AAG | 0.31623 | uM | 9 | 312.50 | 200.50 | 151.00 | 336.50 | 0.4487 | -0.3158 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 252.00 | 336.50 | 0.7489 | 0.3580 | |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 323.00 | 336.50 | 0.9599 | 0.8933 |